OOIR: Observatory of International Research

Papers

(The H4-Index of Drug and Alcohol Dependence is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017	251
Alcohol and other substance use during the COVID-19 pandemic: A systematic review	226
Alcohol use and mental health during COVID-19 lockdown: A cross-sectional study in a sample of UK adults	164
Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis	159
Adverse childhood experiences (ACEs) and substance use disorder (SUD): A scoping review	125
Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance	108
Factors associated with drinking behaviour during COVID-19 social distancing and lockdown among adults in the UK	103
The early impact of COVID-19 on the incidence, prevalence, and severity of alcohol use and other drugs: A systematic review	99
The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder	88
Contingency management for the treatment of methamphetamine use disorder: A systematic review	85
Emotion regulation and substance use: A meta-analysis	84
Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011–2016	78
Patterns of substance use among adolescents: A systematic review	76
Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021	75
Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective	73
Evaluating the impact of COVID-19: A cohort comparison study of drug use and risky sexual behavior among sexual minority men in the U.S.A.	68
Socially-supportive norms and mutual aid of people who use opioids: An analysis of Reddit during the initial COVID-19 pandemic	68
Transition from injecting opioids to smoking fentanyl in San Francisco, California	65
Prevalence and modes of cannabis use among youth in Canada, England, and the US, 2017 to 2019	65
The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study	63
The intersection of gender and drug use-related stigma: A mixed methods systematic review and synthesis of the literature	62
Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden	59
Addressing opioid overdose deaths: The vision for the HEALing communities study	56
Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse	55
The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an inte	54

Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis	53
Drug overdose deaths involving cocaine and psychostimulants with abuse potential among racial and ethnic groups – United States, 2004–2019	52
Adolescent drug use before and during U.S. national COVID-19 social distancing policies	50
Opioid-related overdose mortality in the era of fentanyl: Monitoring a shifting epidemic by person, place, and time	49
Community engagement to implement evidence-based practices in the HEALing communities study	49
Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder	49
Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing communities study	48
Anabolic androgenic steroids, antisocial personality traits, aggression and violence	48
A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic	48
Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017	46
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use	46
Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999–2018	46
Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study	45
Joint perceptions of the risk and availability of Cannabis in the United States, 2002-2018	45
Alcohol and substance use in pregnancy during the COVID-19 pandemic	44
The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: A rapid phone survey in Baltimore, Maryland	44
Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence	43
Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use	43